1020. Development of a Novel Anthrax Vaccine Comprising LF-PA Chimera
Session: Poster Abstract Session: Adult Immunization - Miscellaneous
Friday, October 6, 2017
Room: Poster Hall CD
Background: Bacillus anthracis (BA), the etiological agent of anthrax, secretes protective antigen (PA), lethal factor (LF), and edema factor (EF) as major virulence factors. Among them, PA based vaccines are most indispensable for providing immunity against BA, but the low shelf life limits its reliability. Previous studies revealed that PA domain IV includes B-cell epitopes designated as ID I, ID II, & ID III; among them, ID II and ID III have been found to possess more toxin neutralization activity and produce high antibody titre. Moreover, N-terminal region of both LF and EF carries binding site of PA which are homologous to each other. Here, in this study we have developed and evaluate the vaccine efficacy of chimeric vaccine containing ID II-ID III region of PA and N-terminal region of LF and EF (ID-LFn).

Materials and Methods: ID-LFn was generated by overlapping PCR followed by cloning in pET28a. The recombinant protein was then expressed and purified by Ni-NTA chromatography. Reactivity of ID-LFn with anti-PA/LF/EF antibodies was checked by ELISA. Stability was assessed using Circular Dichroism Spectroscopy. The vaccine potential of ID-LFn was evaluated by toxin neutralization assay, lymphocyte proliferation assay, and cytokine analysis. The protection efficacy was analyzed by challenge studies in mice.

Results: ID-LFn was found to be significantly stable as compared to protective antigen. Anti-ID-LFn antibodies recognized PA, LF as well as EF. Though, the total antibody titre, toxin neutralization activity was found to be less than PA but surprisingly, the protection efficacy of ID-LFn was found similar as PA.

Conclusion: The ID-LFn vaccine might be second next generation vaccine showing equal protection but higher shelf life as PA with the capability of neutralizing PA, LF as well as EF at the same time. Thus, it may prove an efficient and reliable treatment strategy against anthrax.

Somya Aggarwal, Ph.D, Vikas Somani, Ph.D and Rakesh Bhatnagar, Ph.D, Laboratory of Molecular Biology and Genetic Engineering, School of Biotechnology, Jawaharlal Nehru University, New Delhi, India

Disclosures:

S. Aggarwal, None

V. Somani, None

R. Bhatnagar, None

Previous Abstract | Next Abstract >>

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.